1.95
0.00 (0.00%)
| Penutupan Terdahulu | 1.95 |
| Jumlah Dagangan | 10,269 |
| Harga / Jualan (P/S) | 6.31 |
| Harga / Buku (P/B) | 0.860 |
| Julat 52 Minggu |
| Margin Keuntungan | -15.21% |
| Margin Operasi (TTM) | -937.65% |
| EPS Cair (TTM) | -6.00 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -96.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 65.87% |
| Nisbah Semasa (MRQ) | 2.28 |
| Aliran Tunai Operasi (OCF TTM) | -32.35 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -19.19 M |
| Pulangan Atas Aset (ROA TTM) | -21.98% |
| Pulangan Atas Ekuiti (ROE TTM) | -20.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | BioLineRx Ltd. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -1.0 |
| Persekitaran Makro | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | 0.40 |
|
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.08% |
| % Dimiliki oleh Institusi | 0.22% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Banque Cantonale Vaudoise | 30 Jun 2026 | 1 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |